BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 17, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue , and Chief Financial Officer, Vandana Sriram , will attend the

BILLERICA, Mass. --(BUSINESS WIRE)--Jun. 5, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak at the Goldman Sachs 45th Annual Global Healthcare

BILLERICA, Mass. --(BUSINESS WIRE)--May 22, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer Masoud Toloue will speak in a fireside chat at the 2024 Leerink Partners

BILLERICA, Mass. --(BUSINESS WIRE)--May 7, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024 . “Building on the foundation our team developed

BILLERICA, Mass. --(BUSINESS WIRE)--Apr. 29, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Wednesday, May 8, 2024 at 8:30 a.m. E.T.

BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 21, 2024-- Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced a specific partnership path for laboratories interested in offering Tau based research and diagnostic

BILLERICA, Mass. --(BUSINESS WIRE)--Mar. 4, 2024-- Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa ® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 29, 2024-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023 .

BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 26, 2024-- Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release

AdventHealth, Mass General Brigham , Mayo Clinic , MUSC, and UPMC will leverage Quanterix technology and assays to streamline care for Alzheimer’s patients BILLERICA, Mass. --(BUSINESS WIRE)--Feb. 26, 2024-- Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research